NEW YORK, May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in UnitedHealth Group Incorporated ("UnitedHealth Group Incorporated" or the "Company") (NYSE: UNH) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of UnitedHealth Group Incorporated investors who were adversely affected by alleged securities fraud between December 3, 2024 and April 16, 2025. Follow the link below to get more information and be contacted by a member of our tea ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises UnitedHealth Group Incorporated ("UnitedHealth" or the "Company") (NYSE: UNH) investors of a class action representing investors that bought securities between December 3, 2024 and April 16, 2025, inclusive (the "Class Period"). UnitedHealth investors have until July 7, 2025 to file a lead plaintiff motion. Investors are encouraged to contact at ...

Core Viewpoint - UnitedHealth Group is facing significant scrutiny and legal challenges following allegations of undisclosed payments to nursing homes aimed at reducing hospital transfers, which has led to concerns about patient care and corporate practices [1][3][4]. Group 1: Allegations and Legal Issues - Allegations have emerged that UnitedHealth incentivized nursing facilities to limit hospitalizations among Medicare Advantage enrollees, potentially compromising patient care [3][4]. - The company is currently involved in a securities fraud class action lawsuit, with claims that it improperly denied health coverage to enhance profits, leading to regulatory scrutiny [5][6]. - A significant drop in UnitedHealth's stock price occurred after the company reduced its financial guidance for 2025, attributing it to unexpected increases in care activity within its Medicare Advantage business [6][7]. Group 2: Management and Regulatory Scrutiny - The abrupt departure of CEO Andrew Witty on May 13, 2025, has added to the turmoil within the company, resulting in a more than 10% decline in share price on that day [7]. - Federal authorities are investigating whether UnitedHealth engaged in "upcoding," a practice that could inflate Medicare payments by misrepresenting patient diagnoses [8]. Group 3: Investigations and Responses - Hagens Berman, a law firm, is investigating the securities fraud claims against UnitedHealth and is encouraging investors who have suffered losses to come forward [2][9]. - The firm has raised concerns about the implications of the recent allegations on UnitedHealth's commitment to patient care and transparency [10].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of UnitedHealth Group Incorporated regarding a class action lawsuit due to allegations of misleading statements and corporate misconduct during a specified class period [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that UnitedHealth engaged in a corporate strategy of denying health coverage to increase profits and share price [3]. - This strategy led to regulatory scrutiny and public outrage, culminating in the murder of Brian Thompson, which further fueled animosity towards the company [3]. - Following the murder, there was significant public backlash against UnitedHealth, with many Americans expressing support for the accused killer and demanding changes in the company's practices [3]. - Despite the changing corporate environment, UnitedHealth continued to adhere to its previous guidance, which was deemed unrealistic [3]. - The allegations assert that the defendants' public statements were materially false and misleading throughout the relevant period [3]. Class Action Details - The class period for the lawsuit is defined as December 3, 2024, to April 16, 2025 [3]. - Shareholders are encouraged to register for the class action by the deadline of July 7, 2025, to potentially become lead plaintiffs [4]. - Registration allows shareholders to receive updates on the case's progress through a portfolio monitoring software [4]. Firm Background - The Gross Law Firm is recognized nationally for its commitment to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure that companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Financial Disclosures - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization for the second half of the year, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - On October 17, 2024, Elevance reported Q3 2024 financial results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business. The EPS guidance for 2024 was lowered from $37.20 to $33.00, or 11.3% [5]. - Following the Q3 results announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of UnitedHealth Group Incorporated regarding a class action lawsuit alleging that the company engaged in misleading practices that harmed investors [1][2]. Allegations - The complaint claims that UnitedHealth had a corporate strategy of denying health coverage to increase profits and share price [1]. - This strategy led to regulatory scrutiny and public outrage, culminating in the murder of Brian Thompson, which further damaged the company's reputation [1]. - Following the incident, there was significant public animosity towards UnitedHealth, with many Americans expressing support for the accused killer and demanding changes in the company's practices [1]. - Despite the backlash, UnitedHealth continued to provide unrealistic guidance the day before Thompson's murder, which was inconsistent with its changing corporate strategies [1]. - The allegations assert that the defendants' public statements were materially false and misleading throughout the relevant period [1]. Class Action Details - The class period for the lawsuit is from December 3, 2024, to April 16, 2025, with a deadline for shareholders to register as lead plaintiffs by July 7, 2025 [2]. - Shareholders who register will receive updates on the case through portfolio monitoring software [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and illegal business practices, ensuring companies adhere to responsible business conduct [3].

Core Viewpoint - Elevance Health's shares have decreased by 27% over the past year, significantly underperforming the broader market over the last 1, 3, and 5 years [1]. Group 1 - The stock's underperformance is attributed to various reasons that are not detailed in the provided content [1].

Core Viewpoint - Investors in Elevance Health, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its financial guidance and operational costs [1][3]. Summary by Sections Lawsuit Details - The lawsuit alleges that between April 18, 2024, and October 16, 2024, Elevance Health failed to disclose critical information to investors, including the fact that sicker patients with higher acuity remained on Medicaid after redetermination, leading to increased per-patient costs [3]. - It is claimed that the rise in costs was not adequately reflected in Elevance's rate negotiations with states or in its financial guidance for 2024, resulting in materially misleading statements about the company's business and prospects [3]. Participation Information - Investors who suffered losses in Elevance Health are encouraged to contact the Law Offices of Howard G. Smith before July 11, 2025, to participate in the ongoing lawsuit [2]. - Interested parties can reach out via email, phone, or the law firm's website for more information regarding their legal rights and the class action [4][5].

Core Insights - UnitedHealth Group's stock has declined over 50% since April 2025, prompting scrutiny into its revenue generation and key segments [1][13][15] Revenue Generation - UnitedHealth Group operates two primary businesses: UnitedHealthcare and Optum, with revenue generation roughly balanced between the two. In 2024, Optum accounted for 46% of total revenues, while UnitedHealthcare contributed 54% [2][13] - Optum's contribution to overall sales has been increasing, rising from 41% in 2021 to 46% in 2024, while UnitedHealthcare's share decreased from 59% to 54% during the same period [2] UnitedHealthcare Segment - The UnitedHealthcare segment focuses on providing a full range of health benefits and insurance products, currently facing pressure on profit margins due to rising medical costs [3][15] - The Medicare & Retirement division, which serves individuals aged 65 and older, generated $139.5 billion in revenue and $8.4 billion in EBITDA in 2024, representing 25% of the company's total revenue and 23% of its EBITDA. This segment is currently under criminal investigation for possible fraud [4][15] - The Employer & Individual segment generated $74.5 billion in gross revenue and $4.5 billion in EBITDA in 2024, accounting for 13% of the company's revenue and 12% of its total EBITDA [5] - The Community & State division reported $80.6 billion in revenue and $4.9 billion in EBITDA in 2024, making up 15% of the company's total revenue and 13% of its EBITDA [7] - The International segment generated $3.7 billion in revenue with EBITDA of approximately $222 million in 2024, accounting for less than 1% of the company's sales and profits [8] Optum Segment - Optum focuses on modernizing the healthcare system through technology and direct care delivery, with three key sub-segments: Optum Health, Optum Insight, and Optum Rx [9] - Optum Health generated $105.4 billion in gross revenue in 2024, with sales rising at an average rate of 25% since 2021, contributing 24% of the company's total EBITDA [10] - Optum Insight, focusing on data and analytics for the healthcare industry, generated $18.8 billion in sales and $3.6 billion in EBITDA, contributing 9% of the company's total EBITDA [11] - Optum Rx, a pharmacy benefit manager, generated $133.2 billion in gross revenue and $6.8 billion in EBITDA in 2024, accounting for 24% of the company's overall revenues and 18% of total EBITDA [12] Strategic Challenges - UnitedHealth Group is at a pivotal moment, facing scrutiny that impacts its stock and necessitates strategic shifts. Optum's increasing contribution to sales highlights its role in future growth, but challenges include potential political changes affecting the PBM landscape and the ongoing criminal investigation into Medicare fraud [13][15]

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors about its monitoring of cost trends related to the Medicaid "redetermination" process, assuring them that premium rates were sufficient despite rising Medicaid expenses [4]. - The redetermination process led to a significant increase in the utilization of Medicaid members, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance or rate negotiations [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 earnings, missing EPS expectations by $1.33, or 13.7%, and lowered its EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, due to ongoing Medicaid issues [7]. - Following this announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [8].